Auris Medical Holding AG (EARS) Trading Down 2.4%
Auris Medical Holding AG (NASDAQ:EARS) traded down 2.4% during trading on Monday . The stock traded as low as $2.01 and last traded at $2.02, with a volume of 131,011 shares trading hands. The stock had previously closed at $2.07.
Several equities research analysts have recently commented on the stock. Leerink Swann reaffirmed a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Tuesday, July 12th. JMP Securities lowered shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Finally, Needham & Company LLC upped their price target on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, August 19th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.88.
The stock has a 50 day moving average of $3.68 and a 200-day moving average of $3.86. The stock’s market capitalization is $69.69 million.
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.